ASCO 2021: Telaglenastat plus cabozantinib for metastatic kidney cancer
Cell metabolism in renal cell carcinoma (RCC) tumours is disrupted, [...]
ASCO 2021: Cobozantinib plus nivolumab combination for non-clear cell kidney cancer
The cabozantinib/nivolumab combination has been shown to be effective at [...]
Nivolumab/cabozantinib combination approved in EU for first-line kidney cancer treatment
The European Commission has approved the use of the nivolumab [...]
Nivolumab/cabozantinib combination recommended for EMA approval for first-line kidney cancer
The Committee for Medicinal Products for Human Use (CHMP) of [...]
ASCO GU 2021: Comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for advanced papillary kidney cancer
A gene called MET codes for a protein called MET [...]
ASCO GU 2021: Combination of HIF-2α inhibitor and cabozantinib is active in previously treated advanced kidney cancer
In a small phase 2 study presented at the virtual [...]
ASCO GU 2021: Cabozantinib for the treatment of kidney cancer brain metastases
Brain metastases resulting from the spread of renal cell carcinoma [...]
ASCO GU 2021: Nivolumab plus cabozantinib combination for the first-line treatment of advanced kidney cancer
The past couple of years has seen a number of [...]
Cabozantinib plus nivolumab granted FDA approval for first-line treatment of advanced kidney cancer
The Food and Drug Administration (FDA) in the United States has [...]
CB-839/cabozantinib combination in advanced/metastatic kidney cancer fails to improve progression-free survival
The US Food and Drug Administration (FDA) has granted the [...]
